Results 241 to 250 of about 807,581 (353)

Self‐Management Interventions in Young Adults (18–30 Years) With Type 1 Diabetes, Sickle Cell Disease, and Inflammatory Bowel Disease: A Scoping Review

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Fluctuating chronic conditions (FCC) in young adults aged 18–30 years, such as type 1 diabetes (T1D), sickle cell disease (SCD), and inflammatory bowel disease (IBD), present unique self‐management challenges due to unpredictable symptom patterns that disrupt daily life.
Reham Almabadi, Lawrence Doi, Colin Chandler, Huda Alamri   +3 more
wiley   +1 more source

Man with abdominal pain

Journal of the American College of Emergency Physicians Open, 2020
Sophie Leflot, Blaise Anthonissen, Etienne Danse, Eric Goffin   +3 more
doaj   +1 more source

Emerging therapeutic approaches for treating abdominal pain. [PDF]

J Can Assoc Gastroenterol
Jimenez-Vargas NN, Parkar N, Takami K, Wood HM, Lomax AE, Reed DE, Vanner SJ.   +6 more
europepmc   +1 more source

Filariasis presenting as acute abdominal pain: The role of imaging and image-guided intervention in diagnosis.

, 2015
Natasha N Metha, Vashali S Dalavi, Nikit Mehta   +2 more
openalex   +2 more sources

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Pheochromocytoma: A rare cause of abdominal pain identified in a family medicine outpatient department setting. [PDF]

J Family Med Prim Care
Teja S, Aravindan N, Ajith AV, Sachdeva A, Mathew J, Kumar S.   +5 more
europepmc   +1 more source

A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bepirovirsen, an antisense oligonucleotide in development for the treatment of chronic hepatitis B virus (HBV) infection, is administered from glass vials as a subcutaneous (SC) injection by healthcare professionals (HCPs). A ready‐to‐use prefilled syringe (PFS) assembled with a safety syringe device (SSD) has been developed to make ...
Amir S. Youssef, Poonam Shah, Maxwell Hu, Helene Plein, Abhishek Roy, Ravi Sharma, Sarah Mole, Magdalena Blazejczyk, Wendy Cross, Brian Spears, Samuel Pak, Rejbinder Kaur, Robert Elston, Dickens Theodore, Marjan Hezareh, Ahmed Nader   +15 more
wiley   +1 more source

Abdominal computed tomography use in the emergency department among children with abdominal pain: a retrospective analysis. [PDF]

Int J Emerg Med
Khafaja S, Rizk SS, El Hayek S, Yazbeck N.   +3 more
europepmc   +1 more source

954 Carbohydrate Digestion in Congenital Sucrase Isomaltase Deficient and Recurrent Abdominal Pain Children Assesed by 13C- Starch Breath Test

, 2010
Claudia C. Robayo‐Torres, Antone R. Opekun, Roberto Quezada‐Calvillo, Maricela Diaz‐Sotomayor, Susan S. Baker, Buford L. Nichols   +5 more
openalex   +1 more source

Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant

Clinical Pharmacology &Therapeutics, EarlyView.
Fezolinetant is a first‐in‐class, selective, non‐hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause. In a phase 2b clinical study (n = 352), nine study participants experienced elevations in serum transaminases exceeding three times the upper limit of normal.
Jace C. Nielsen, Jeffrey L. Woodhead, Brett A. Howell, Lisl K. M. Shoda, Dolly A. Parasrampuria, Jiayin Huang, Megumi Iwai, Faith D. Ottery, Xuegong Wang, Marci English, Kentaro Miyazaki, Paul B. Watkins   +11 more
wiley   +1 more source